Sialorrhea Treatment Market Scope And Analysis

Report Code : TIPRE00033418
Category : Life Sciences

No. of Pages : 150

Buy Now

Sialorrhea Treatment Market Scope and Key Players Analysis by 2030

Buy Now

Sialorrhea Treatment Market Report Scope

Report Attribute	Details
Market size in 2022	US$ 695.06 Million
Market Size by 2030	US$ 1,042.37 Million
Global CAGR (2022 - 2030)	5.2%
Historical Data	2020-2022
Forecast period	2022-2030
Segments Covered	By Medical Therapy Pharmacologic Therapy and Radiotherapy By End User Hospitals Specialty Clinics Homecare Settings
Regions and Countries Covered	North America US Canada Mexico Europe UK Germany France Russia Italy Rest of Europe Asia-Pacific China India Japan Australia Rest of Asia-Pacific South and Central America Brazil Argentina Rest of South and Central America Middle East and Africa South Africa Saudi Arabia UAE Rest of Middle East and Africa
Market leaders and key company profiles	Pfizer Inc F Hoffmann La Roche Ltd Mylan N V Fresenius Kabi AG Hikma Pharmaceuticals PLC Novartis AG Teva Pharmaceutical Industries Ltd Bristol Myers Squibb Company GSK Plc

Competitive Landscape and Key Companies:

Pfizer Inc, F. Hoffmann-La Roche Ltd, Mylan N.V., Fresenius Kabi AG, Hikma Pharmaceuticals PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Bristol Myers Squibb Company, GSK Plc., Bayer AG, and Sun Pharmaceutical Industries Ltd. are among the prominent players operating in the global sialorrhea treatment market. These companies focus on the development of new technologies, advancements in existing products, and expansion of geographic footprint to meet the growing consumer demand worldwide and expand their product range in specialty portfolios. Companies operating in the global sialorrhea treatment market are implementing various inorganic and organic strategies. A few of them are mentioned below:

In August 2021, Merz Therapeutics, a business of the Merz Group and a leader in the field of neurotoxins, was granted the use of XEOMIN for the symptomatic treatment of chronic sialorrhea in children and adolescents aged 2 to 17 years and weighing ≥ 12 kg due to neurodevelopmental disorders/neurological on EU level. The US Food and Drug Administration approved it in December 2020, and the Russian Federal Service for Surveillance in Healthcare August 2021.
In February 2023, Proveca Pharma Ltd, a pharmaceutical company that specializes in medicines for children, provided Sialanar (glycopyrronium bromide) to children suffering from severe sialorrhea due to chronic neurological disorders in France.